Advertisement

Topics

Biotech Is Well-Positioned To Outperform

17:31 EDT 20 Jun 2017 | Topix

The FDA remains supportive of new drug treatments and we believe the regulatory environment under Trump will continue to be favorable. Health care has been one of the most unpopular areas in the market for more than two years - particularly biotechnology stocks.

Original Article: Biotech Is Well-Positioned To Outperform

NEXT ARTICLE

More From BioPortfolio on "Biotech Is Well-Positioned To Outperform"

Advertisement
Quick Search
Advertisement
Advertisement